Certara, the leading provider of in silico drug development technologies, to be bought by EQT

On Tuesday 11 July 2017 Arsenal Capital Partners announced to be in the process to sell its portfolio company Certara to the private equity firm EQT

This deal values the Contract Research Organisation (CRO) at $850 million and marks EQT’s second major investment in the U.S. healthcare sector (following a $2.35 billion deal to buy up Press Ganey Holdings, a provider of patient satisfaction surveys, according to Reuters)

Certara is a leading decision support technology and consulting organization committed to optimizing drug development and improving health outcomes. Certara’s solutions, which span drug discovery through patient care, use the most scientifically-advanced modeling and simulation technologies and regulatory strategies to increase the probability of regulatory and commercial success. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies.

Thanks to its acquisitions, the services provided by EQT will now span from physiologically based pharmacokinetic modeling and simulation to pharmacometrics to commercial optimization and regulatory writing. Arsenal will retain an unspecified minority stake in Certara, and the company’s current management team, including CEO Edmundo Muniz, M.D., Ph.D., who joined the company in June 2014 from Kirax, will stay on.

Read the full article

Date: 04/08/2017 | Tag: | News: 640 of 1557
All news


More news


More events

Subscribe to the VPH Institute Newsletter


Read all the newsletters of the VPH Institute